Clinical Trials Using Plerixafor
Clinical trials are research studies that involve people. The clinical trials on this list are studying Plerixafor. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Scleroderma Treatment with Autologous Transplant (STAT) Study
This phase II trial studies how well giving cyclophosphamide and anti-thymocyte globulin together followed by peripheral blood stem cell transplant (PBSCT) and mycophenolate mofetil works in treating patients with systemic scleroderma (SSc). Stem cells are collected from the patient's blood and stored prior to treatment. To store the stem cells patients are given colony-stimulating factors, such as filgrastim (G-CSF) or chemotherapy (cyclophosphamide) to help stem cells move from the bone marrow to the blood so they can be collected and stored. After storage, patients are then given high-dose chemotherapy, cyclophosphamide, and immunosuppression with anti-thymocyte globulin to suppress the immune system to prepare for the transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and immunosuppression. After the stem cells have “engrafted” and have matured enough to support the immune system at approximately 2-3 months, patients are given a medication called mycophenolate mofetil (MMF) or Myfortic. This medication is given to prevent worsening or reactivation of SSc and is referred to as maintenance therapy.
Location: 12 locations
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Whole Brain Radiation Therapy with Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients with Glioblastoma
This phase II trial studies how well whole brain radiation therapy works with standard temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain tumor). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Plerixafor is a drug that may prevent recurrence of glioblastoma after radiation treatment. Giving whole brain radiation therapy with standard temozolomide chemo-radiotherapy and plerixafor may work better in treating patients with glioblastoma.
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
This is an open label, multicenter, Phase 1 / 2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.
Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan
TCR Genetically Engineered PBMC and PBSC after Melphalan Conditioning Regimen in Treating Participants with Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple myeloma that has come back or does not respond to treatment. The melphalan conditioning chemotherapy makes room in the patient’s bone marrow for new blood cells (PBMC) and blood-forming cells (stem cells) to grow. Giving NY-ESO-1 TCR PBMC and stem cells after the conditioning chemotherapy is intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer. Giving NY-ESO-1 TCR PBMC and PBSC after melphalan may work better at treating multiple myeloma.
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR after a Myeloablative Conditioning Regimen to Treat Patients with Advanced Cancer
This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body. The conditioning chemotherapy makes room in the patient’s bone marrow for new blood cells (PBMC) and blood-forming cells (stem cells) to grow. Giving NY-ESO-1 TCR PBMC and stem cells after the conditioning chemotherapy is intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer.
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Stem Cell Collection with or without Bortezomib in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
This randomized phase II trial studies collecting stem cell with or without bortezomib treatment in patients with multiple myeloma undergoing autologous stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth which may cause cancer cells to die. Autologous stem cell transplant is a standard procedure in which bone marrow stem cells are removed from the patient's blood, treated in the laboratory, and stored while the patient is treated with chemotherapy and / or radiotherapy to kill any remaining cancer cells that are in the body. After intensive treatment, the stem cells are then given back to the patient to replace the blood-forming cells that were destroyed by chemotherapy and / or radiation therapy. Some of the cancer cells however remain in the stem cells that are given back to the patient which may lead to poor disease free survival. Doctors want to know whether giving bortezomib before stem cell collection may decrease the number of cancer cells remaining in the sample of collected stem cells. It is not yet known whether giving bortezomib before stem cell collection is more effective than standard stem cell collection without bortezomib in decreasing the number of stem cells contaminated with cancer cells.
Location: University of Kansas Cancer Center, Kansas City, Kansas
Plerixafor in Increasing CD34+ Hematopoietic Progenitor Cells in Patients with Sickle Cell Disease
This phase I trial studies the side effects and the best dose of plerixafor in increasing cluster of differentiation 34 (CD34) blood forming cell (hematopoietic progenitor cell) count in patients with sickle cell disease. Plerixafor may help move CD34 cells from the bone marrow to the blood. These cells are then collected, changed in the laboratory to make normal oxygen carrying molecules (hemoglobin) in red blood cells and then given back to the patient.
Location: 2 locations